- Poster presentation
- Open Access
Arterial spin labeling CMR quantifies increased perfusion in hearts of mice treated with cardioprotective, AAV9-mediated EcSOD gene therapy prior to myocardial infarction
© French et al; licensee BioMed Central Ltd. 2010
- Published: 21 January 2010
- Myocardial Infarction
- Myocardial Perfusion
- Infarct Size
- Capillary Density
- Arterial Spin Label
Experimental myocardial infarction (MI), direct gene transfer with adeno-associated viral (AAV) vectors and CMR in mice are powerful tools for studying the roles of individual genes in MI and post-MI left ventricular (LV) remodeling. Arterial spin labeling (ASL) enables the quantification of myocardial perfusion (MP) by CMR, but is sensitive to variable heart rates and irregular respiration, prohibiting accurate measurement early after MI. We developed a cardio-respiratory gated (CRG) ASL method that is insensitive to these factors to measure MP in mice.
The objective of this study was to test the hypotheses that AAV9-mediated overexpression of extracellular superoxide dismutase (EcSOD) from the cardiac Troponin-T (cTnT) promoter would increase capillary density and protect the heart against myocardial infarction (MI). Furthermore, we tested the hypothesis that an improved method of ASL could quantitate the elevation in MP resulting from increased capillary density.
CRG-ASL was developed on a 7 T MR system and employed to measure MP both before and 4 wks after gene therapy. AAV vectors were cross-packaged into AAV9 capsids expressing EcSOD or eGFP from the cTnT promoter (AcTnTEcSOD or AcTnTeGFP), and were injected IV into 4-5 week-old C57Bl/6 mice (3 × 1011 vp/mouse). Four weeks after injection, MI was induced by a 30 min coronary occlusion. Infarct size and area at risk (A@R) were measured 24 h later by TTC and Phthalo blue staining, respectively. Capillary density was measured 4 wks post injection in remote myocardium immunostained for CD31.
CRG-ASL quantifies the increase in MP resulting from cardioprotective gene therapy with EcSOD. Transcriptional targeting with the cTnT promoter in combination with the high-efficiency AAV9 capsid provides cardioprotective gene therapy from a single IV injection. AAV9-mediated overexpression of EcSOD from the cTnT promoter significantly increases capillary density, improves myocardial perfusion and reduces infarct size in the murine heart.
This article is published under license to BioMed Central Ltd.